Geoffrey Lim Uy MD

Hematologic Oncology

Professor of Medicine, Washington University School of Medicine

4500 Forest Park AveDiv IM Bone Marrow Transplant 5TH 6TH 8TH FLSt. Louis, MO 63108
Phone+1 314-454-8304
Fax+1 314-454-5902

Dr. Uy is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Uy's full profile Already have an account?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2003 - 2007
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2001 - 2003
WashU MedicineClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2020 - 2029
MO State Medical License 2002 - 2027
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Modular), Allscripts, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification Follow My Health, Jardogs, 2013-2014, 2016-2017

Clinical Trials

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
ACTIVE_NOT_RECRUITING
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
COMPLETED
PHASE1, PHASE2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
COMPLETED
PHASE2

Publications & Presentations

PubMed

Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance).
Wellington F Silva, Jun Yin, Michaela Liedtke, David F Claxton, Noreen Fulton
Blood Advances. 2026-08-25
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrózek
Leukemia. 2026-08-01
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh
Blood Advances. 2026-07-30

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$10.8 Million Grant Supports Cutting-Edge Leukemia ResearchDecember 16th, 2024
World Leaders in Ending Blood CancerNovember 14th, 2024
You Make the Call: How Would You Treat This Transplant-Ineligible Patient with Ph+ ALL?September 30th, 2021

Grant Support

Clinician Scientist in LeukemiaWASHINGTON UNIVERSITY2023–2028
Clinician Scientist in LeukemiaWASHINGTON UNIVERSITY2023–2028
Targeting Leukemia Stromal Interactions In AMLNational Cancer Institute2009–2011